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Abstract
Atypical retinoids are potent inducers of apoptosis,
but activation of the apoptotic pathway seems to be
independent of retinoid receptors. Previous studies
with a novel adamantyl retinoid, ST1926, have shown
that apoptosis induction is associated with an early
genotoxic stress. To better understand the relevance
of these events, we have selected a subline of the H460
lung carcinoma cell line resistant to ST1926. Resistant
cells exhibited cross-resistance to a related molecule,
CD437, but not cross-resistance to agents with dif-
ferent mechanisms of action. In spite of a lack of de-
fects in intracellular drug accumulation, induction of
DNA strand breaks in resistant cells required expo-
sure to a substantially higher concentration, which
was consistent with the degree of resistance. At drug
concentrations causing a similar antiproliferative ef-
fect (IC80) and a comparable extent of DNA lesions in
sensitive and resistant cells, the apoptotic response
was a delayed and less marked event in resistant
cells, thus indicating a reduced susceptibility to apop-
tosis. In spite of recognition of DNA lesions in resis-
tant cells, as supported by phosphorylation of p53
and histone H2AX, resistant cells exhibited no activa-
tion of the mitochondrial pathways of apoptosis. Fol-
lowing exposure to equitoxic drug concentrations, only
sensitive cells exhibited a typical stress/DNA damage
response, with activation of the S-phase checkpoint.
The cellular resistance to ST1926 reflects alterations
responsible for a reduced generation of DNA lesions
and for an enhanced tolerance of the genotoxic stress,
resulting in lack of activation of the intrinsic pathway
of apoptosis. The defective DNA damage response,
accompanied by a reduced susceptibility to apoptosis
in resistant cells, provides further support to the in-
volvement of genotoxic stress as a critical event in me-
diating apoptosis induction by ST1926.
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Introduction
The pharmacologic interest of retinoids in cancer therapy and
chemoprevention is related to their ability to modulate a variety
of critical biologic functions including cell growth and differen-
tiation. Whereas the broad biologic effects of classic retinoids
are mediated by retinoid receptors [1], the antiproliferative and
proapoptotic activities of novel synthetic retinoid-related mole-
cules (RRMs or atypical retinoids) are described to be inde-
pendent of receptor-mediated transcriptional activity [2,3]. The
best known compound belonging to this class of proapoptotic
RRMs is CD437, which was reported to be selective for RARg
[4]. Although a number of potential targets for drug action have
been identified and several aspects of drug-induced apoptosis
have been elucidated, the molecular mechanism of action of
RRMs is only partially understood [2–5]. The intrinsic apoptotic
pathway involving mitochondrial damage has been implicated
in CD437-induced apoptosis [6]. Cellular effects of atypical
retinoids also involve p53 activation and a p53-dependent in-
crease of cell death receptors and, therefore, the activation of
extrinsic pathway of apoptosis [7]. However, it is likely that
multiple pathways are implicated in the apoptotic action of
atypical retinoids and the contribution of different events may
be dependent on the cellular context [2,5]. A better understand-
ing of the molecular events mediating the inhibition of cell
growth and apoptosis induction by atypical retinoids could
provide a rational basis for the design of more effective treat-
ments also in combination with other agents.
Recently, a related compound of this series, ST1926, was
found to be a potent inducer of apoptosis in a large panel of
human tumor cells and showed efficacy against solid tumor
models derived from human ovarian carcinoma, lung carci-
noma, and melanoma at well-tolerated doses [8,9]. The in-
creased antiproliferative and apoptogenic potency of ST1926,
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compared to CD437, in spite of a modest RAR activation
supports the view that the cellular effects of the novel agent
are independent of retinoid receptors [9,10].
The pattern of cellular response to the adamantyl reti-
noid, ST1926, suggested that the induction of genotoxic
stress was implicated in mediating drug-induced apopto-
sis [9]. To identify the critical determinants of cellular sensi-
tivity to ST1926, we characterized a lung carcinoma cell
line, H460/ST1926 (R9A), which was selected following
continuous in vitro exposure to ST1926. A comparison of
the extent of DNA lesions and of the cellular response in
parental and resistant cells to ST1926 is consistent with
a critical role of DNA damage response in determining cell
fate and suggests that tolerance to drug-induced genotoxic
stress contributes to resistance status.
Materials and Methods
Cell Lines and Culture Conditions
The human lung carcinoma cell line, H460, and its sub-
line, R9A, selected for resistance to ST1926, were main-
tained in RPMI 1640 (Bio-Whittaker, Verviers, Belgium)
supplemented with 10% FBS (Life Technologies, Inc., Gai-
thersburg, MD). The R9A subline was selected by cultur-
ing cells for 6 months in culture medium containing 2 mM
ST1926. R9A cells were subcultured in the absence of the
drug and a resistance index (ratio between the IC50 of re-
sistant and sensitive cells) of 200 was maintained for at
least 3 months. Both sensitive and resistant cells were char-
acterized by wild-type p53.
Drugs and Antibodies
ST1926 (synthesized as described by Cincinelli et al.
[8]) and CD437 were supplied by Prof. L. Merlini (DISMA,
University of Milan, Italy). Stock solutions of ST1926 and
CD437 were prepared in dimethylsulfoxide (DMSO) and
stored at 20jC, prior to further dilution in culture medium.
The highest final concentration of DMSO in culture medium
was 0.5%. Doxorubicin (Pharmacia UpJohn, Milan, Italy) was
dissolved in water; paclitaxel (Indena, Milan, Italy) and
ZD1839 (Astra Zeneca, Manlesfield, Cheshire, UK) were
dissolved in DMSO; and cisplatin (Platinex) (Bristol Myers
Squibb, Rome, Italy) was dissolved in 0.9% NaCl before use.
Killer-TRAIL was supplied by Alexis Biochemicals (Lausen,
Switzerland). Lonidamine (LND) (Angelini, Rome, Italy) was
dissolved in 2.3% N-methyl-D-glucamine (NMG) and further
diluted in water to a final concentration of 3.2 mg/ml imme-
diately prior to use.
The following antibodies were used: anti–phospho-p38
MAP kinase (Thr 180/Tyr 182) and anti–phospho-p44/42
MAP kinase (Thr 202/Tyr 204) (New England Biolabora-
tories, Beverly, MA); anti–phospho-JNK (Thr 183/Tyr 185),
anti-p38 (C-20), and anti-p73 (E-4) (Santa Cruz Biotech-
nology, Santa Cruz, CA); anti-MAPK 1/2 (ERK 1/2-CT) and
anti–g-H2AX (Upstate Biotechnology, Lake Placid, NY);
anti–phospho-Akt (Ser473), anti–SAPK/JNK, anti–cleaved
caspase-3, and anti–phospho-p53 (Ser15) (Cell Signal-
ing Technology, Beverly, BA); anti–PBKa/Akt (Transduc-
tion Laboratories, Lexington, KY); anti-p53 and anti–Bcl-2
(Dako, Glostrup, Denmark); anti-p21, anti–RPA-2, and anti–
caspase-9 (NeoMarker, Union City, CA); anti-BAX and anti–
caspase-8 (BD Pharmigen/Becton Dickinson, Mountain View,
CA); anti–PARP-1 (Oncogene Science, Uniondale, NY); anti–
cytochrome C (BD Pharmigen/Becton Dickinson); and anti-
actin (Sigma, St. Louis, MO).
Cell Sensitivity Studies
Cell sensitivity to drugs was determined by growth inhi-
bition assay. Cells were seeded in duplicate into six-well
plates and exposed to g-rays or to the drugs for 24 hours
(ST1926) or 72 hours (ST1926, CD437, paclitaxel, ZD1839,
and LND). In all cases, adherent cells were trypsinized and
counted 72 hours after the beginning of treatment by a cell
counter (Coulter Electronics, Luton, UK). IC50 values, de-
rived from dose–response curves, were defined as drug
concentrations producing 50% inhibition of cell growth. The
reported values represents the mean ± standard deviation
(SD) of at least three independent experiments.
The effect of the combination of ST1926 with TRAIL
on cell growth was assessed by sulforhodamine B (SRB)
assay. Cells were seeded in 96-well plate and incubated
for 24 hours with ST1926 or TRAIL alone or in combina-
tion. After 48 hours from drug removal, cells were subjected
to SRB staining. Drug interactions, expressed as combina-
tion index (CI) values, were calculated according to the
following formula:
CI ¼ ðSFa  SFbÞ
SFða þ bÞ =100
where SF indicates the survival fraction observed with each
drug (a and b) or with the cotreatment (a + b). According to
the analysis described by Drewinko et al. [11], CI values
indicate the following interaction: CI > 1, synergism; CI = 1,
additivity; CI < 1, antagonism.
Drug Uptake
The intracellular drug content was measured follow-
ing incubation of the cells with 0.3 mM ST1926 for 1 hour.
Cells were then washed with phosphate-buffered saline
(PBS) and incubated in drug-free medium for different
time intervals to measure drug retention. Cells were lysed
in PBS containing 0.1% sodium dodecyl sulphate (SDS) and
ST1926 was extracted two times by ethylacetate. The or-
ganic phase was dried in a nitrogen flux and the pellet
was resuspended in ethanol. Samples were left for 2 hours
at 20jC and then centrifuged. Supernatants were ana-
lyzed by HPLC (Beckman Instruments, Fullerton, CA). The
separation was performed by isocratic elution (80% metha-
nol, 0.02% trifluoroacetic acid), with a flow rate of 1 ml/min
on a LiChroCART4-4/Lichrospher 100 RP-18, 5 mm (Merck,
Whitehouse Station, N.J.). The detection was performed
with a spectrofluorimetric detector RF-10AXL Shimadzu at
kexc 330 nm and kem 475 nm. All data were expressed as
mean (ng ST1926 / mg total proteins) ± SD.
668 Resistance to Apoptosis in ST1926-Resistant Cells Zuco et al.
Neoplasia . Vol. 7, No. 7, 2005
Cell Cycle Analysis
Cells were exposed to drug concentrations correspond-
ing to the IC80 value calculated after 72 hours of treatment
(i.e., 0.2 and 20 mM for H460 and R9A cells, respectively).
At different times, cells were washed, fixed in ice-cold 70%
ethanol, and stored at 20jC. After rehydration in PBS,
cellular DNA was stained with 10 mg/ml propidium iodide
(PI) (Sigma) in PBS containing RNase A (66 U/ml) (Sigma),
for 18 hours. Cell cycle distribution was determined by a
FACScan flow cytometer (Becton Dickinson) and data were
analysed by Cell Quest software. At least 10,000 cells were
analyzed for DNA content.
Detection of Apoptosis
Apoptosis was detected by terminal deoxynucleotidyl
transferase–mediated deoxyuridine triphosphate nick-end
labelling (TUNEL assay) and annexin V staining.
For the TUNEL assay, cells were fixed in 4% parafor-
maldehyde, for 60 minutes, at room temperature, washed,
and resuspended in ice-cold PBS. The In Situ Cell Death
Detection Kit Fluorescein (Roche, Mannheim, Germany)
was used according to the manufacturers’ instructions and
the samples were analysed by flow cytometry using Cell
Quest software (Becton Dickinson). For the annexin re-
action, cells (1  105) were suspended in 100 ml of binding
buffer (10 mM HEPES–NaOH, pH 7.4, 140 mM NaCl,
2.5 mM CaCl2), 5 ml of annexin V–FITC (BD Pharmigen/
Becton Dickinson), and 5 ml of PI (final concentration, 1 mg/ml)
for 15 minutes. After the addition of 400 ml of binding buffer,
cells were analysed on a FACScan.
Alkaline Elution Assay
DNA single-strand breaks were detected by the alka-
line elution method [12]. Cells were incubated in the pres-
ence of 0.08 mCi/ml [14C]thymidine (Amersham Biosciences,
Amersham, UK) for 30 hours, and then for 18 hours in the ab-
sence of labeled thymidine to chase the DNA-incorporated
radioactivity. After treatment with different concentrations of
ST1926 for 6 hours, cells were immediately processed for
alkaline elution as previously described [9]. A positive con-
trol consisting of cells irradiated with 0.4 Gy was used as
a reference.
Immunofluorescence Staining of g-H2AX
H460 and R9A cells were seeded on slides in six-well
plates and, 24 hours later, treated with ST1926 at 0.2 and
20 mM, respectively, corresponding to equitoxic (IC80) con-
centrations, for 3 hours. At the end of treatment, cells were
fixed in 2% paraformaldehyde in PBS for 5 minutes, washed
in PBS, permeabilized in 100% methanol at 20jC for
20 minutes, and blocked with PBS containing 1% bovine
serum albumin and 0.1% Tween 20 (PBA) for 15 minutes.
Then, samples were incubated with anti–g-H2AX mouse
monoclonal antibody for 1 hour, followed by AlexaFluor
594–conjugated goat antimouse antibody (Molecular
Probes, Eugene, OR) for 1 hour. Slides were then washed
in PBA, incubated with 2 mg/ml Hoechst 33341 (Sigma) for
2 minutes, mounted with Mowiol, and examined by a fluo-
rescence microscope.
Western Blot Analysis
Cells were rinsed twice with cold PBS added with 0.1 mM
sodium orthovanadate and lysed in hot sample buffer [9].
After determination of protein concentration, whole-cell ex-
tracts were separated by SDS polyacrylamide gel electro-
phoresis (PAGE) and transferred onto nitrocellulose filters.
The filters were incubated with primary antibodies over-
night and with peroxidase-conjugated secondary antibodies
at room temperature for 1 hour. Immunoreactive bands
were revealed by using the enhanced chemiluminescence
detection system from Amersham Bioscences or Pierce
(Rockford, IL).
Measurement of Cytochrome C Release from Mitochondria
H460 and R9A cells were exposed to ST1926 (IC80, 0.2
and 20 mM, respectively) or LND (IC80, 155 mM) for different
times. Floating and adherent cells were harvested and
cytosolic extracts were prepared as described [13]. Briefly,
cells were homogenized in ice-cold lysis buffer (20 mM
HEPES–KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM
EDTA, 1 mM EGTA, 250 mM sucrose, 0.5 mM phenylme-
thylsulfonyl fluoride, 10 mg/ml leupeptin, 10 mg/ml aprotinin,
and 10 mg/ml trypsin inhibitor) by 25 strokes in a Dounce
homogenizer and centrifuged at 20,000g for 20 minutes.
Supernatants were stored at 70jC until gel electrophore-
sis. Cytosolic protein extracts were run on 20% SDS-PAGE
and processed for Western blot analysis as described above.
Measurement of Dwm by Flow Cytometry
Mitochondrial permeability was assessed as already de-
scribed [14]. H460 and R9A cells were treated for 24 hours
with ST1926 at 0.2 and 20 mM, respectively. A total of 5 105
cells was incubated with CMTMRos (150 nM) (Molecular
Probes) for 15 minutes in culture medium at 37jC and 5%
CO2. Samples were harvested, washed in PBS, and imme-
diately analyzed by a flow cytometer (Becton Dickinson).
Analysis of Gene Expression by RT-PCR
Total cellular RNA was isolated from ST1926-treated
and ST1926-untreated cells by using a commercially avail-
able kit (Talent, Trieste, Italy). Two micrograms of RNA was
reversed-transcribed into cDNA by the use of oligo(dt) pri-
mers and Moloney murine leukemia virus reverse transcrip-
tase (Invitrogen, Milan, Italy). To amplify the TR3 transcript,
the 5V-tcatggacggctacacag-3V/5V-gtaggcatggaatagctc-
3Vprimers were used. The amplified fragment was 517 bp.
PCR conditions were as follows: 95jC, 9 minutes, for
1 cycle; 95jC, 1 minute, 52jC, 1 minute; 72jC, 1 minute, for
30 cycles followed by 10-minute extension at 72jC. In the
case of b-actin, which was used as a control (actin primers:
5V-gaaactaccttcaactccatc-3V and 5V-ggcggctccatcctggcctcg-3V),
the annealing temperature was 62jC and the number of
base pairs was 300. The amplification products were sepa-
rated on 1.5% agarose gel containing ethidium bromide and
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UV-visualized by using a VDS Image Master (Amersham
Pharmacia Biotech Italia, Cologno Monzese, Italy).
Results
Pattern of Cross-Resistance
The ST1926-resistant H460 subline (R9A) exhibited a
stable resistant phenotype in the absence of selective pres-
sure. The resistance index of the subline R9A to ST1926
was very high and somewhat dependent on the exposure
time (Table 1). When evaluated in terms of cell growth inhi-
bition, the resistant subline displayed cross-resistance to
CD437 but not to other antitumor agents characterized by
a different mechanism of action (Table 1).
Drug Uptake
To determine whether drug resistance could be related
to defects in intracellular drug accumulation, drug uptake
in sensitive and resistant cells was measured following a
1-hour exposure to the same drug concentration (Figure 1).
Drug uptake and retention were comparable in the two
cell lines.
DNA Damage
Using the alkaline elution method, no significant extent
of DNA damage could be detected in resistant cells at
concentrations of ST1926 below 1 mM (i.e., at concentra-
tions producing DNA damage and antiproliferative effects in
sensitive cells). Thus, comparative studies were performed
on the two cell lines after 6 hours of drug treatment in the
range of cytotoxic concentrations for each cell line. As shown
in Figure 2A, formation of DNA breaks in resistant cells
required a substantially higher concentration of ST1926,
but drug concentrations producing similar antiproliferative
effects induced a comparable amount of DNA damage. The
presence of DNA damage could be detected under these
conditions by the formation of g-H2AX foci (Figure 2B).
H2AX phosphorylation (g-H2AX) has been reported to be
specific for the sites of DNA double-strand breaks [15,16].
This event could be detected early after treatment, as already
reported for other DNA-damaging agents [17]. Indeed,
g-H2AX foci were observed in 100% of both cell lines
treated with ionizing radiation (20 Gy). After a 3-hour ex-
posure to equitoxic concentrations (IC80) of ST1926, 55%
of H460 and 46% of R9A cells were markedly positive
for g-H2AX staining.
RPA-2, a DNA single-strand binding protein essential for
DNA replication, recombination, and repair, becomes rapidly
phosphorylated after DNA damage [18]. In our cell system,
RPA-2 appeared phosphorylated in H460 cells after 6 and
24 hours of exposure to ST1926, whereas a persistent
downregulation of the protein was observed in the resistant
cells (Figure 2C) following exposure to equitoxic drug con-
centrations (IC80).
Cell Cycle Perturbation
A quite different perturbation of cell cycle progression
was found in the two cell lines after treatment with equitoxic
concentrations (IC80) of ST1926 (Figure 3). In H460 cells,
ST1926 caused a persistent accumulation of cells in the
G1/S phases. A time-dependent increase of sub-G1 cells was
consistent with the occurrence of apoptotic DNA fragmen-
tation. The treatment caused a different profile of cell cycle
distribution in resistant cells with no evidence of S-phase
arrest. Resistant cells exhibited a transient accumulation in
G2 at 24 hours and a late appearance of sub-G1 cells at
72 hours, likely reflecting cell death.
Apoptosis Induction and Caspase Activation
Figure 4 shows the extent of apoptotic cell death induced
in each cell line at different exposure times to a single drug
concentration corresponding to the IC80 (0.2 and 20 mM
for H460 and R9A cells, respectively). Apoptosis induction
was less marked and delayed in the resistant cells. After a
48-hour exposure, a significant level (22%) of apoptosis was
detectable only in H460 cells. The different onset of apop-
tosis in the two cell lines was clearly documented by the
annexin V binding assay, which revealed early manifes-
tations of apoptosis in resistant cells only at 72 hours of
Table 1. Pattern of Cross-Resistance.
Drug Exposure (hours) IC50 (mM)*
H460 R9A
ST1926 24 0.21 ± 0.01 24 ± 8
ST1926 72 0.06 ± 0.03 12 ± 4.2
CD437 72 0.12 ± 0.08 >40
Doxorubicin 1 0.27 ± 0.11 0.24 ± 0.1
Cisplatin 1 19.3 ± 1.5 20 ± 3
Paclitaxel 72 0.0051 ± 0.0005 0.0035 ± 0.0003
ZD1839 72 23 ± 2 17 ± 4
g-Ray (Gy) 2.50 ± 0.4 3.37 ± 0.67
TRAIL (ng/ml) 24 5.82 ± 1.14 1.39 ± 0.05
LND 72 118 ± 10 93 ± 10
*The antiproliferative effect was determined at 72 hours after treatment by
cell counting. IC50 values were derived from the dose– response curves for
each compound.
Figure 1. Drug uptake and release of ST1926. H460 (n) and R9A (z) cells
were exposed to the same drug concentration (0.3 M) for 1 hour. Then, cells
were incubated in drug-free medium and drug retention was determined at
the indicated times. The arrow indicates the end of treatment.
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treatment (Table 2). At this time, under our conditions, the
treatment induced a marked antiproliferative effect in both
cell lines (IC80). The extent of overall apoptosis in sensitive
cells could be underestimated as a consequence of early
onset of apoptosis. The only moderate induction of apopto-
sis in R9A-resistant cells at a concentration that strongly
inhibited proliferation indicated that the cytostatic activity of
the drug was more pronounced than its cytotoxic activity in
resistant cells compared to parental cells.
Cleavage of caspases 8, 9, and 3 was already detectable
after a 24-hour exposure to ST1926 in H460 cells (Figure 5).
Accordingly, a concomitant time-dependent cleavage of
Figure 2. Induction of DNA damage in H460 and R9A cells by ST1926. (A) DNA single-strand breaks induced by ST1926. H460 (n) and R9A (z) cells were
exposed to increasing drug concentrations for 6 hours and then DNA breaks were measured by the alkaline elution assay. The results, expressed as rad
equivalents, are the mean ± SD of three independent experiments. (B) Immunofluorescence staining for c-H2AX. Cells were treated with equitoxic concentrations
(IC80) of ST1926 for 3 hours and stained with mouse anti – c-H2AX antibody and AlexaFluor 594–conjugated goat antimouse Ig second antibody (red). Nuclei were
stained with Hoechst 33342 (blue). (C) RPA-2 phosphorylation following exposure to equitoxic concentrations of ST1926 (IC80) for the indicated times. The arrow
indicates the phosphorylated RPA-2. The results of one experiment representative of two are reported.
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PARP-1, one of the caspase substrates in apoptosis, was
observed. The pattern of caspase activation was substan-
tially different in R9A cells because no activation of caspase
9 was found at any time until 72 hours of treatment. A weak
activation of caspases 3 and 8 was associated with cleav-
age of PARP-1, which was barely detectable starting at
24 hours of treatment. The reduced activation of caspases
in R9A cells is in agreement with a lower extent of apoptosis
detected by the TUNEL and annexin binding assays.
A typical mitochondrial response to proapoptotic stimuli
involves the cytosolic release of cytochrome C, a caspase ac-
tivator, and mitochondrial transmembrane depolarization [6].
Both events were detected in sensitive cells but no changes
were found in the resistant cells exposed to ST1926 (IC80)
(Figure 6, A and B). This finding was consistent with the
lack of activation of caspase 9 in resistant cells. The dif-
ferent mitochondrial response did not reflect a defect at
mitochondrial level in resistant cells because a cytotoxic
concentration (IC80) of LND, a mitochondrial-targeting drug
[19,20], caused the release of cytochrome C (Figure 6C),
consistent with the finding that the drug induced a compa-
rable extent of apoptosis in the two cell lines (50 ± 5% and
57 ± 10% in sensitive and resistant cells, respectively).
The resistant subline retained sensitivity to TRAIL, thus
supporting no defects in the extrinsic apoptotic pathway.
However, the death receptor ligand showed synergistic
Figure 3. Cell cycle distribution of H460-sensitive and R9A-resistant cells at different times after treatment with equitoxic concentrations of ST1926 (IC80). One
experiment representative of three is shown.
Figure 4. Apoptosis induced by ST1926. Cells were exposed for 48 and 72 hours to 0.2 and 20 M ST1926 corresponding to the IC80 value in H460 and R9A cells,
respectively. Apoptosis was detected by TUNEL assay and determined by FACS analysis.
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interaction with ST1926 only in sensitive cells (Figure 7). This
observation was consistent with a lack of activation of the
mitochondrial-regulated pathway and therefore a lack of co-
operation between the extrinsic and intrinsic pathways.
Modulation of Apoptosis-Related Factors
Figure 8A shows the expression of apoptosis-related
proteins at 24, 48, and 72 hours of treatment with equitoxic
concentrations (IC80) of ST1926. In the parental cell line, an
increase of expression of p53 and p21 was already detect-
able after 24 hours of treatment, together with an upregu-
lation of Bax. In resistant cells, a less marked drug-induced
upregulation of p21 was transiently detected only at 24 hours,
consistently with a marginal activation of p53. Moreover,
in contrast to ST1926-induced upregulation of Bax in paren-
tal cells, drug treatment caused a slight downregulation
of Bax in R9A cells, clearly evident after prolonged expo-
sure. Bcl-2 expression was not modulated by treatment in
both cell lines. An early (6 hours) upregulation of p73 was
detected in H460 cells, whereas no modulation of p73 expres-
sion could be detected in resistant cells even with high (equi-
toxic) drug concentrations (Figure 8B). p53 phosphorylation
could be detected in resistant cells at concentrations 50- to
100-fold higher than in parental cells. This finding was
consistent with the different extent of DNA damage found
in the two cell lines.
We examined the expression of TR3, another transcrip-
tion factor described to be upregulated by DNA damage and
to be involved in the induction of apoptosis through the
mitochondrial pathway [21]. Again, in contrast to the R9A
cell line, H460 cells revealed an early upregulation of TR3
transcripts most evident after 6 hours of treatment (Figure 9).
Modulation of AKT and MAP Kinases
Because a differential basal or drug-induced activation
of Akt and MAP kinases, which are involved in pathways
regulating proliferation, survival, or apoptosis, might be de-
terminant in the cell sensitivity to drug treatment, the state
of activation of Akt and ERKs, JNKs, and p38 was examined
in H460 and ST1926-resistant R9A cells. The drug effects
were compared using equitoxic or equivalent concentra-
tions. Cells were exposed for 6 hours to concentrations of
ST1926 corresponding to IC50 and IC80 values for H460
cells (0.06 and 0.2 mM, respectively) and resistant cells
(12 and 20 mM, respectively). Cell lysates were analyzed
by Western blot analysis by the use of phospho-specific
antibodies detecting the activated kinases. In spite of a
reduced Akt expression in the resistant cells, Akt phos-
phorylation was similar in the two cell lines. ST1926 treat-
ment did not affect Akt activation or expression (Figure 10).
Similarly, activation of the ERKs was not modulated by
the drug. However, whereas the protein expression of
ERKs was similar in the two cell lines, the extent of basal
Table 2. Apoptosis Detection by Annexin V Binding Assay in H460 and R9A
Cells Treated with ST1926 (IC80).
Exposure Time (hours) H460 R9A
Early* Latey Early* Latey
24 10 ± 3 0 3 ± 3 0
48 14 ± 4 27 ± 4 6 ± 3 9 ± 4
72 2 ± 0 48 ± 8 11 ± 4 22 ± 4
*Percentage of cells in an early stage of apoptosis (i.e., cells stained
positively for annexin V–FITC and negatively for PI).
yPercentage of cells in a late stage of apoptosis (i.e., stained positively for
both annexin V–FITC and PI).
Figure 5. Cleavage of caspases and PARP-1 in cells exposed to ST1926. Western blot analysis with specific antibodies was performed after 24, 48, and 72 hours
of exposure to 0.2 M and 20 M ST1926 in H460 and R9A cells, respectively (IC80 at 72 hours). Actin is shown as a control for protein loading.
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phosphorylation was consistently higher in R9A cells than
in the parental cells. Atypical retinoids, including ST1926,
have been reported to activate the stress MAP kinases, p38
and JNKs [9]. H460 and R9A cells did not differ in terms of
expression or phosphorylation of these kinases in the absence
of the drug. However, a dose-dependent activation of either
p38 or JNK2 was induced by ST1926 only in the sensitive
H460 cells, whereas no activation of stress kinases could be
detected in R9A cells, even when treated with equitoxic con-
centrations of ST1926.
Discussion
The comparison of ST1926 effects on sensitive and resis-
tant lung carcinoma cells indicates a substantially different
pattern of cellular response and provides additional insights
into the critical molecular events involved in antiproliferative/
proapoptotic activities of adamantyl atypical retinoids. The
most relevant observations of the present study are: 1) the
selective resistance of the subline R9A to ST1926 was as-
sociated with a reduced and delayed apoptosis, and did not
implicate a reduced uptake of the drug; 2) the resistance to
the antiproliferative effects of ST1926 was accompanied
by a lower induction of genotoxic stress; however, equitoxic
drug concentrations produced a comparable extent of DNA
damage in the two cell lines; 3) under equitoxic conditions,
DNA damage response and cellular stress response, clearly
evident in sensitive cells, were barely detectable in the re-
sistant cells; and 4) the reduced susceptibility to apoptosis
of R9A cells was associated with a lack of activation of the
intrinsic mitochondrial-regulated pathway.
Our data indicate that in parental H460 cells, ST1926-
induced apoptosis involved caspases 3, 9, and 8, thus impli-
cating both intrinsic and extrinsic pathways of apoptosis. It is
conceivable that the two cascades converge, resulting in a
prompt and efficient cell death. In contrast, in resistant cells,
no evidence was found of caspase 9 activation, but only
a weak activation of caspases 8 and 3. This pattern of re-
sponse suggests a lack of contribution of the mitochondrial-
regulated apoptotic pathway. This interpretation was also
supported by a lack of either cytochrome C release or mito-
chondrial transmembrane depolarization in resistant cells. Thus,
in spite of the presence of a functional cell death receptor–
mediated pathway in resistant cells, as suggested by the
sensitivity to TRAIL, the available results support that the
reduced susceptibility to ST1926-induced apoptosis could
be the consequence of a loss of cooperation between the
intrinsic and extrinsic pathways. Accordingly, a synergistic
interaction between ST1926 and TRAIL was observed in
H460 parental cells, but not in R9A cells.
Several lines of evidence indicate that CD437 and other
related compounds induce apoptosis in a retinoid receptor–
independent manner [2]. Synthetic derivatives of a novel
Figure 6. Effect of ST1926 (A) or LND (C) on the release of cytochrome C
into the cytosol. In (A), the two cell lines were exposed to equitoxic con-
centrations (IC80) of ST1926; in (C), R9A cells were exposed to the IC80 value
of LND (155 M). The cytosolic extracts were prepared after the indicated
times of drug exposure. (B) Analysis of mitochondrial transmembrane poten-
tial in H460 and R9A cells treated with ST1926 at their respective IC80 values.
Cells were labeled with CMTMRos 24 hours after treatment with solvent
(grey) or ST1926 (white), and then analyzed by flow cytometry to measure
changes in Dwm (see Materials and Methods section for details).
Figure 7. Combination index (Drewinko index) for the interaction between
ST1926 and TRAIL. H460 (n) and R9A (z) cells were exposed to each drug or
combination for 24 hours, using a single equitoxic concentration of ST1926
(i.e., 0.08 M and 8 M for H460 and R9A cells, respectively). The antiprolif-
erative effect was determined after a 48-hour incubation in drug-free medium.
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series, including ST1926 and MM002, display a low ability
to activate RARg, and are characterized by an almost com-
plete loss of typical retinoid features [4,8,22]. Although a
number of potential targets for apoptosis induction have
been identified, the precise mechanism of action of adaman-
tyl atypical retinoids remains unclear at the molecular level.
Multiple mechanisms have been described in different tumor
cells [5] and it is possible that the relevance of the reported
effects is cell type–specific. In a number of cell lines derived
from solid tumors, a typical feature of cellular response to
ST1926 exposure is a marked activation of p53 [7,9]. It is well
known that several stress stimuli, including genotoxic stress,
activate p53 and induce apoptosis through p53-mediated
upregulation of proapoptotic factors.
In a previous study performed in an ovarian carcinoma
cell system, we have documented that ST1926 induces a
significant extent of DNA breaks after a short-term exposure
to the retinoid [9]. DNA adduct formation by CD437 has been
reported [3,23]. The nature of the genotoxic stress, also
detected in ST1926-treated H460 cells, is unknown, but it
could not be ascribed to oxidative stress because the cel-
lular effects of the drug were not modified by the use of
antioxidant agents (not shown). The presence of genotoxic
stress was supported by the pattern of cellular response, as
documented by activation of p53 and p73, upregulation of
p21 and Bax, and cell cycle arrest at the S-phase checkpoint
in H460-sensitive cells. This response, together with activa-
tion of caspase 9 implicated in the mitochondrial-regulated
pathway, is consistent with a p53-dependent apoptosis. Our
study indicated that the induction of appreciable DNA breaks
Figure 8. (A) Expression of p53, p21WAF1, Bax, and Bcl-2 in ST1926-sensitive (H460) and ST1926-resistant (R9A) cells treated with solvent () or ST1926 at the
respective IC80 (+), for the indicated times. (B) Effect of ST1926 on p73 expression and p53 phosphorylation (Ser15) after cell exposure for 6 hours to both
equivalent and equitoxic concentrations, corresponding to the respective IC50 and IC80 values. Whole-cell extracts were prepared and analyzed by Western blot
analysis. Actin is shown as a control of protein loading.
Figure 9. RT-PCR analysis of TR3 expression in H460 and R9A cell lines.
RNA was isolated after 2 or 6 hours of treatment with solvent () or ST1926
(0.2 M for H460 and 20 M for R9A cells). Amplification products with
primers for TR3 and -actin, separated on agarose gel, are shown.
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by drug treatment was substantially reduced in resistant
cells. Indeed, DNA breaks were detectable in resistant
cells only at cytotoxic concentrations, thus supporting the
relevance of genotoxic stress in the mechanism of drug
action. In spite of recognition of DNA lesions, as evidenced
by drug-induced formation of g-H2AX foci and p53 phos-
phorylation, the resistant cells were characterized by a de-
ficient DNA damage response, as indicated by a loss of cell
cycle arrest at DNA damage checkpoint during DNA synthe-
sis and by a marginal activation of cell death pathways, re-
sulting in cellular tolerance to the genotoxic stress.
The lack of activation of the mitochondrial pathway of
cell death in resistant cells could not be ascribed to a defect
in the mitochondrial functions because LND, a mitochondrial
targeting drug, was effective as apoptosis inducer. The alter-
ations associated with the resistant phenotype, including
marginal activation of p53 and p21, lack of activation of
p73, and downregulation of Bax, support a defective DNA
damage signaling occurring upstream of the mitochondria.
The lack of drug-induced transcription of TR3 in resistant
cells is also consistent with this interpretation because TR3
functions as a proapoptotic factor by interaction with mito-
chondrial membrane [24–26]. The mechanism by which
atypical retinoids induce TR3 is not fully understood. In
previous studies, the upregulation of TR3 by CD437 has
been ascribed to MEF2 or c-jun activation mediated by p38
or JNK, respectively [21,27]. However, no definitive explana-
tion for the activation of cellular stress response has been
provided [28]. The observation that TR3 expression can be
induced by a variety of stimuli, including DNA damage, is
worth noting [29,30].
The activation of stress-inducible molecules, such as JNK
and p38, is part of a cellular response to genotoxic stress
[31]. Although JNK may be implicated in some forms of
apoptotic cell death, depending on the biologic context
[32], activation of signaling pathways involving MAPK by
DNA-damaging agents likely reflects a protective response
[33,34]. Such a similar role has been documented in ovarian
carcinoma cells because inhibition of stress-activated ki-
nases resulted in an enhancement of ST1926-induced apop-
tosis [9]. In the drug-sensitive ovarian carcinoma cell line, the
pattern of cellular response to the atypical retinoid, ST1926,
was comparable to that observed in H460 cells in terms
of activation of DNA damage response and modulation of
proteins/genes implicated in genotoxic stress, including the
activation and upregulation of AP-1 transcription factors. The
latter event reflects the activation of stress-activated MAPK
pathways. cDNA array analysis of transcription in H460 cell
provided evidence of increased expression of c-jun, a mem-
ber of AP-1 complex (not shown). Thus, modulation of AP-1
complex appears to involve not only phosphorylation of the
protein but also enhanced transcription. Again, this modu-
lation likely reflects a protective cellular response to the
genotoxic stress because the activation of AP-1 transcrip-
tion factors has been already described following treatment
with other genotoxic agents (e.g., UV radiation) and is me-
diated by stress-activated protein kinases [35]. In addition, in
the present study, cytotoxic concentrations of ST1926 are
shown to induce an appreciable apoptosis also in resistant
R9A cells without activating JNKs and p38, thereby suggest-
ing that stress kinases did not mediate ST1926-induced
apoptotic signals in the H460 cell system. The alterations
responsible for resistance to apoptosis in R9A cells mapped
upstream of events inducing the activation of JNK/p38 and
the induction of the intrinsic apoptotic pathway. In addition,
the high basal activation of the ERKs in R9A cells might
also contribute to the resistant phenotype as a component
of a survival pathway [36].
In conclusion, the development of resistance in H460
cells reflects alterations in the mechanisms involved in the
drug induction of DNA lesions and in cellular response to
the genotoxic stress. The attenuated DNA damage response
and the absence of stress response to cytotoxic concentra-
tions of ST1926 in resistant cells are consistent with the in-
terpretation that resistant cells might be defective in signal
transduction pathways triggered by the genotoxic lesions.
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